E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Swedish Orphan Biovitrum
1 program
1
PacritinibPhase 1Small Molecule1 trial
Active Trials
NCT06538181RecruitingEst. Feb 2029

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
Swedish Orphan BiovitrumPacritinib

Clinical Trials (1)

NCT06538181Swedish Orphan BiovitrumPacritinib

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Start: Feb 2025Est. completion: Feb 2029
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space